research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib
A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Refractory alopecia in lupus treated with tofacitinib — a case-based review
Tofacitinib helped regrow hair in a lupus patient with alopecia.
research Ritlecitinib (Litfulo)
Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research Efficacy and Safety of Treatment with Combine Mycophenolate Mofetil and Corticosteroid for Lupus Nephritis:A Multicenter Open-label Study
The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
Methotrexate plus prednisolone had the fewest serious side effects.
research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
research SDRIFE Induced by Tofacitinib
Tofacitinib can cause a rare rash called SDRIFE, which resolves after stopping the drug.
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
research Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Differential impact of environmental factors on systemic and localized autoimmunity
Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Combined Ultrasound and Microneedle for Enhanced Transdermal Delivery: Synergistic Mechanisms and Therapeutic Advances
Combining ultrasound and microneedles improves drug delivery through the skin.
research Minoxidil and Dexamethasone Eluting Nanofiber Dressing for Cutaneous Wound Healing in Rat
The new wound dressing with minoxidil and dexamethasone could speed up healing and reduce scarring in rats.
research Where it all went right
Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
research Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation
Many medications may be linked to cognitive disorders, but most lack warnings on labels.
research STABILITY INDICATING AN LC-ESI-MS/MS METHOD FOR THE QUANTIFICATION OF MINOXIDIL IN PHARMACEUTICAL DOSAGE FORMS
The method accurately measures Minoxidil in drugs and is reliable for routine use.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Dissolving microneedles: an advanced approach for transdermal drug delivery
Dissolving microneedles offer efficient, minimally invasive drug delivery through the skin.
research Skin Complications Associated with Interferon-β Treatment in Patients with Multiple Sclerosis, Tehran in 2021 - 2
Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.